

Table S1, SDC

PICO #	Patient Population	Intervention	Comparator	Outcome(s) of Interest
WAIT LISTED PATIENTS				
1	Wait-listed with compensated cirrhosis and HCC	Antiviral Therapy (i.e. pre vs. post)	No antiviral therapy	HCC Progression pre and post-LT Wait-list mortality Survival post-LT SVR
2	Wait-listed with decompensated cirrhosis without HCC	Antiviral Therapy (i.e. pre vs. post)	No antiviral therapy	Wait-list survival Post-LT survival HCV recurrence post-LT HCC progression pre-post Improvement in decompensation SVR
3	Wait-listed with decompensated cirrhosis and HCC	Antiviral Therapy (i.e. pre vs. post)	No antiviral therapy	HCC Progression pre and post-LT Wait-list mortality Survival post-LT Improvement in decompensation SVR
SPECIAL POPULATIONS				
4	HCV-HIV coinfected patient without HCC	Antiviral therapy (i.e. pre vs. post)	No antiviral therapy	Wait-list survival Post-LT survival SVR
5	HCV negative recipient (including previously treated HCV)	HCV positive donor	HCV negative donor	Wait-list survival Post-LT survival HCV infection

	positive recipient)			
LIVER TRANSPLANT RECIPIENTS				
6	Vlremic post-LT	Antiviral therapy early (prior to disease)	Antiviral therapy upon documentation of significant disease	Post-transplant survival Cholestatic hepatitis SVR Advanced fibrosis Extrahepatic complications (renal, DM)
5	Post-LT with cholestatic hepatitis	Antiviral therapy with SOF/NS5A ± RBV	Antiviral therapy with other drug classes	Post-transplant survival including re-LT SVR Advanced fibrosis
7	Post-LT recurrent cirrhosis	Antiviral therapy	No antiviral therapy	Survival Improvement in decompensation (MELD, CTP) SVR